Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.73 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 4/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.61 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.61 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.61 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.61 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.61 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.61 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.61 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27924635 | 0.98 | KMT2A (0.71) | KMT2ASMN1; SMN2EPHX2MEN1ALDH1A1 | |
| SCHEMBL9341104 | 0.92 | KMT2A (0.83) | KMT2ASMN1; SMN2EPHX2MEN1ALDH1A1 | |
| SCHEMBL31658991 | 0.92 | KMT2A (0.83) | KMT2ASMN1; SMN2EPHX2MEN1ALDH1A1 | |
| SCHEMBL8516755 | 0.89 | SMN1; SMN2 (0.90) | KMT2ASMN1; SMN2EPHX2MEN1ALDH1A1 | |
| SCHEMBL11721101 | 0.87 | KMT2A (0.71) | KMT2ASMN1; SMN2EPHX2MEN1ALDH1A1 | |
| SCHEMBL29135742 | 0.87 | KMT2A (0.71) | KMT2ASMN1; SMN2EPHX2MEN1ALDH1A1 | |
| SCHEMBL30372162 | 0.87 | SMN1; SMN2 (0.91) | KMT2ASMN1; SMN2EPHX2MEN1ALDH1A1 | |
| SCHEMBL1503134 | 0.87 | KMT2A (0.65) | KMT2ASMN1; SMN2EPHX2MEN1ALDH1A1 | |
| SCHEMBL11765496 | 0.86 | KMT2A (0.69) | KMT2ASMN1; SMN2EPHX2MEN1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL11716759 | 0.86 | KMT2A (0.69) | KMT2ASMN1; SMN2EPHX2MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117924171-A | Phenanthrone derivative and synthesis method thereof | 华南理工大学 | 2024-04-26 | — | — | CN | claimed |
| CN-117776958-A | Aromatic hydrocarbon carboxylic acid meta-position alkylation product and synthesis method thereof | 华南理工大学 | 2024-03-29 | — | — | CN | claimed |
| CN-114890856-A | Method for synthesizing 2,2' -biphenyl-1-carboxylic acid derivative | 华南理工大学 | 2022-08-12 | — | — | CN | claimed |
| EP-2751109-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | Incyte Corporation (US) | 2014-07-09 | — | — | EP | claimed |
| CN-102268027-B | Amide Au (III) complex with antitumor activity | UNIV HEBEI | 2013-11-13 | — | — | CN | claimed |
| WO-2013033569-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2013-03-07 | — | — | WO | claimed |
| EP-2166846-A1 | INHIBITORS OF JANUS KINASES | Merck Sharp & Dohme Corp. (US) | 2010-03-31 | — | — | EP | claimed |
| WO-2008156726-A1 | INHIBITORS OF JANUS KINASES | MERCK & CO., INC. (US) | 2008-12-24 | — | — | WO | claimed |
| CN-1411809-A | Usage and composition of pyridine onium derivative for curing application | TORENTO PHARMACEUTICAL CO LTD (IN) | 2003-04-23 | — | — | CN | claimed |
| US-12570645-B2 | Uses of p53 x-ray co-crystal structures | PMV PHARMACEUTICALS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260027097-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20250319063-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2025-10-16 | — | — | US | disclosed |
| US-12419880-B2 | Companion diagnostic tool for mutant p53 reactivating compounds | PMV PHARMACEUTICALS, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250213555-A1 | SUBSTITUTED TETRAHYDROFURAN ANALOGS AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-07-03 | — | — | US | disclosed |
| CN-1329597-A | Pyridinium derivatives for treatment of diabetic and aging-related vascular complications | TORRENTO PHARMACEUTICAL CO LTD (IN) | 2002-01-02 | — | — | CN | disclosed |
| CN-1023479-C | Process for preparing monoamide derivatives of ethylenediamine | HOFFMANN LA ROCHE (CH) | 1994-01-12 | — | — | CN | disclosed |
| US-4764522-A | ANTIDEPRESSANT, ANTIPARKINSON DISEASE | HOFFMANN-LA ROCHE INC. (US) | 1988-08-16 | — | — | US | disclosed |
| CN-85107182-A | Process for preparing monoamide derivatives of ethylenediamine | — | 1987-04-08 | — | — | CN | disclosed |
| US-4200640-A | TREATING CIRCULATORY DISEASES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1980-04-29 | — | — | US | disclosed |
| US-4031226-A | ANTIEMETIC, PSYCHOTROPIC | JANSSEN PHARMACEUTICA N.V. (BE) | 1977-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250319063-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | TP53, TP53BP1, KRAS | KMT2A 2916/4885SMN1; SMN2 3942/4885EPHX2 3572/4885 |
| US-20250213555-A1 | SUBSTITUTED TETRAHYDROFURAN ANALOGS AS MODULATORS OF SODIUM CHANNELS | TRPV1, SCN1A, TRPA1 | KMT2A 3862/4885SMN1; SMN2 227/4885EPHX2 4059/4885 |
| US-20260027097-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, BRCA1 | KMT2A 601/4885SMN1; SMN2 3167/4885EPHX2 4538/4885 |
| US-12570645-B2 | Uses of p53 x-ray co-crystal structures | TP53, TP53BP1, ERCC2 | KMT2A 3878/4885SMN1; SMN2 4175/4885EPHX2 4473/4885 |
| US-12419880-B2 | Companion diagnostic tool for mutant p53 reactivating compounds | TP53, TP53BP1, KRAS | KMT2A 3244/4885SMN1; SMN2 3967/4885EPHX2 4307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.